4D Pharmaceuticals, a leading UK-based company focusing on live biotherapeutics with drug-like functionality to treat a range of diseases, announced additional data from its  Part A of its Phase I/II trial of MRx-4DP0004, an orally-delivered single strain Live Biotherapeutic for the treatment of asthma. The company said that the phase I/II trial is a multi-center, double-blind, placebo-controlled study in patients with partly controlled asthma taking long-term medication in order to assess the safety and tolerability of MRx-4DP0004. They revealed that in addition to meeting the primary endpoint and safety profile, MRx-4DP0004 showed activity across multiple secondary endpoints compared to placebo, generating promising preliminary signals of clinical activity which support progression into Part B of the Phase I/II study.